ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $17,641 | -74.5% | 11,095 | 0.0% | 0.00% | -100.0% |
Q4 2022 | $69,122 | -58.9% | 11,095 | -55.8% | 0.00% | -66.7% |
Q3 2022 | $168,000 | +19.1% | 25,095 | +13.6% | 0.01% | 0.0% |
Q2 2022 | $141,000 | -32.5% | 22,095 | -51.0% | 0.01% | -25.0% |
Q1 2022 | $209,000 | -24.0% | 45,095 | -18.2% | 0.01% | -20.0% |
Q4 2021 | $275,000 | -38.5% | 55,095 | +48.5% | 0.01% | -44.4% |
Q3 2021 | $447,000 | +27.4% | 37,095 | +123.5% | 0.02% | +28.6% |
Q2 2021 | $351,000 | -46.9% | 16,595 | -29.6% | 0.01% | -54.8% |
Q1 2021 | $661,000 | +120.3% | 23,570 | +104.1% | 0.03% | +93.8% |
Q4 2020 | $300,000 | -29.7% | 11,550 | +0.4% | 0.02% | -44.8% |
Q3 2020 | $427,000 | -40.5% | 11,500 | -17.9% | 0.03% | -44.2% |
Q2 2020 | $718,000 | +51.8% | 14,000 | -6.7% | 0.05% | +23.8% |
Q1 2020 | $473,000 | -47.1% | 15,000 | 0.0% | 0.04% | -40.0% |
Q4 2019 | $894,000 | +94.8% | 15,000 | +19.8% | 0.07% | +70.7% |
Q3 2019 | $459,000 | -1.3% | 12,525 | +25.2% | 0.04% | +13.9% |
Q2 2019 | $465,000 | – | 10,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |